Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 192 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR Can Some Women Treated for Endometrial Cancer Forgo Radiation after Surgery? July 15, 2019 Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 Newest Gerber Baby is Child of Breast Cancer Survivor June 29, 2021 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 Load more HOT NEWS Metastatic Breast Cancer: ESMO Clinical Practice Guideline Family Brings Joy & Raises Money With Their Extravagant Christmas Light... GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,...
